We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$524M
1-Year Est. Return
164.42%
This Fund
S&P 500
This Quarter
Est. Return
+3.41%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$118M
AUM Growth
-$12M
(-9.2%)
Cap. Flow
-$24.6M
Cap. Flow
% of AUM
-20.81%
Top 10 Holdings %
Top 10 Hldgs %
43.16%
Holding
94
New
22
Increased
10
Reduced
13
Closed
18
Avg Time Held
3.2
quarters
Top 10 Avg Time Held
3.3
quarters
Top 20 Avg Time Held
3.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$7.61M |
| 2 |
XNPT
XENOPORT, INC.
XNPT
|
+$2.71M |
| 3 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$2.26M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
+$1.72M |
| 5 |
CYAD
Celyad Oncology SA American Depositary Shares
CYAD
|
+$1.61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$18.3M |
| 2 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
+$12.1M |
| 3 |
Molecular Templates, Inc.
MTEM
|
+$2.54M |
| 4 |
AtriCure
ATRC
|
+$1.98M |
| 5 |
Curis
CRIS
|
+$720K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.36% |
| 2 | Miscellaneous | 17.06% |
| 3 | Technology | 0.33% |
| 4 | Financials | 0.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
AtriCure
ATRC
$2.89B
| $13.5M | 11.43% |
548,611
-88,820
| -14% | -$1.98M |
2013 Q2
8 quarters
|
|
|
2
AbbVie
ABBV
$485B
| $7.83M | 6.62% |
+116,581
| New | +$7.61M |
2015 Q2
0 quarters
|
|
|
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
| $5.24M | 4.43% |
366,554
| – | – |
2013 Q2
8 quarters
|
|
|
ACHN
4
DELISTED
Achillion Pharmaceuticals
ACHN
| $4.25M | 3.6% |
480,300
+238,700
| +99% | +$2.26M |
2014 Q3
3 quarters
|
|
5
Rigel Pharmaceuticals
RIGL
$881M
| $3.56M | 3.01% |
110,974
| – | – |
2014 Q4
2 quarters
|
|
|
ZSPH
6
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $3.52M | 2.97% |
67,100
+28,000
| +72% | +$1.38M |
2015 Q1
1 quarter
|
|
7
BioCryst Pharmaceuticals
BCRX
$2.06B
| $3.31M | 2.8% |
221,656
+55,000
| +33% | +$625K |
2014 Q3
3 quarters
|
|
8
Insulet
PODD
$9.58B
| $3.29M | 2.78% |
106,018
| – | – |
2013 Q2
8 quarters
|
|
9
DELISTED
Windtree Therapeutics Inc
WINT
| $3.26M | 2.76% |
342,491
-2,500
| -0.7% | -$35.1K |
2013 Q2
8 quarters
|
|
|
XNPT
10
DELISTED
XENOPORT, INC.
XNPT
| $3.25M | 2.75% |
531,032
+414,773
| +357% | +$2.71M |
2013 Q2
8 quarters
|
|
|
AERI
11
DELISTED
Aerie Pharmaceuticals
AERI
| $2.77M | 2.34% |
156,842
-3,400
| -2% | -$62.3K |
2014 Q3
3 quarters
|
|
|
DSCI
12
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $2.68M | 2.26% |
373,918
| – | – |
2013 Q2
8 quarters
|
|
|
SGYP
13
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $2.64M | 2.23% |
+317,563
| New | +$1.54M |
2015 Q2
0 quarters
|
|
|
OTIC
14
DELISTED
Otonomy, Inc.
OTIC
| $2.56M | 2.17% |
111,466
+61,466
| +123% | +$1.72M |
2015 Q1
1 quarter
|
|
|
AGTC
15
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $2.41M | 2.04% |
157,192
+47,869
| +44% | +$918K |
2015 Q1
1 quarter
|
|
16
Protalix BioTherapeutics
PLX
$222M
| $2.4M | 2.03% |
123,079
| – | – |
2013 Q2
8 quarters
|
|
17
DELISTED
BioTelemetry, Inc.
BEAT
| $2.22M | 1.88% |
235,645
| – | – |
2013 Q2
8 quarters
|
|
|
CLVS
18
DELISTED
Clovis Oncology, Inc.
CLVS
| $2.03M | 1.72% |
23,090
-310
| -1% | -$26.5K |
2014 Q3
3 quarters
|
|
19
Stereotaxis
STXS
$106M
| $1.98M | 1.67% |
1,716,078
| – | – |
2013 Q2
8 quarters
|
|
20
DELISTED
Masimo
MASI
| $1.78M | 1.51% |
46,010
-19,990
| -30% | -$716K |
2013 Q2
8 quarters
|
|
|
CYNA
21
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
| $1.73M | 1.46% |
+94,824
| New | +$1.56M |
2015 Q2
0 quarters
|
|
|
EVFM
22
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
| $1.66M | 1.4% |
2,047
-29
| -1% | -$18.6K |
2014 Q4
2 quarters
|
|
23
Ascendis Pharma A/S
ASND
$14.7B
| $1.65M | 1.4% |
93,541
| – | – |
2015 Q1
1 quarter
|
|
|
CYAD
24
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
| $1.56M | 1.32% |
+30,000
| New | +$1.61M |
2015 Q2
0 quarters
|
|
25
Tvardi Therapeutics
TVRD
$13.9M
| $1.54M | 1.31% |
+3,527
| New | +$1.36M |
2015 Q2
0 quarters
|
|
Similar funds
4WM
BB
A
HW
DAM
SDWIA
SCA
BHPW
DAFNA Capital Management's Q2 2015 Portfolio in Review
As of Q2 2015, DAFNA Capital Management held 94 positions worth $118M, down 9.2% from $130M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
DAFNA Capital Management withdrew a net $24.6M in Q2 2015, closing 18 positions and reducing 13 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $18.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 65% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, DAFNA Capital Management opened a new position in AbbVie worth $7.83M.
- DAFNA Capital Management's largest Q2 2015 buy was AbbVie: 116,581 shares worth $7.83M.
- DAFNA Capital Management added most to XENOPORT, INC. in Q2 2015, an estimated $2.71M increase.
- DAFNA Capital Management's biggest Q2 2015 reduction was AtriCure, cutting an estimated $1.98M.
- DAFNA Capital Management fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $18.3M.
- DAFNA Capital Management's ten largest holdings make up 43% of its $118M portfolio in Q2 2015.
- DAFNA Capital Management opened 22 new positions and closed 18 in Q2 2015.
- DAFNA Capital Management's portfolio value fell 9.2% quarter-over-quarter to $118M.
Based on DAFNA Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.